16:50 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Biogen, Eisai's BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 at the Alzheimer's Association International Conference showing that the anti-β-amyloid therapy slowed cognitive decline by as much as 30%. However,...
21:56 , Jul 26, 2018 |  BC Extra  |  Company News

Biogen, Eisai AD readout leads to stock dive

Biogen Inc. (NASDAQ:BIIB) sank $39.09 (10%) to $344.74 on Thursday after reporting detailed data from a Phase II trial of Alzheimer's disease candidate BAN2401. Although the data showed that the anti-β amyloid therapy slowed cognitive...
23:50 , Jul 25, 2018 |  BC Extra  |  Clinical News

BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 Wednesday at the Alzheimer's Association International Conference showing that the anti-β amyloid therapy slowed cognitive decline by as much as...
03:32 , Jul 6, 2018 |  BC Extra  |  Clinical News

BAN2401 slows AD progression at 18 months

Biogen Inc. (NASDAQ:BIIB) gained $58.67 (20%) to $357.48 on Friday, adding about $12.3 billion in market cap, on new data for its Alzheimer's disease candidate BAN2401. Biogen and partner Eisai Co. Ltd. (Tokyo:4523) reported secondary...
23:01 , Jun 22, 2018 |  BC Extra  |  Preclinical News

Alzheimer's disease linked to herpesvirus

Researchers from the Icahn School of Medicine at Mount Sinai and colleagues found traces of mild strains of herpesvirus in the brains of patients with Alzheimer's disease, adding evidence to previous theories that some viruses...
19:02 , May 31, 2018 |  BC Innovations  |  Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
22:03 , May 10, 2018 |  BC Extra  |  Preclinical News

‘Nanosweepers’ could degrade beta amyloid to treat Alzheimer’s

Researchers at Beijing’s National Center for Nanoscience and Technology and colleagues published a paper in Nature Communications describing a self-destructive "nanosweeper" based on multifunctional peptide-polymers that improved memory deficits after capturing and degrading extracellular deposits...
16:31 , May 4, 2018 |  BioCentury  |  Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
00:38 , Feb 15, 2018 |  BC Extra  |  Clinical News

Biogen slips on Phase III AD studies

Biogen Inc. (NASDAQ:BIIB) lost $20.91 to $296.08 on Wednesday after EVP and CMO Alfred Sandrock said the company will enroll a total of an additional 510 patients in the Phase III ENGAGE and EMERGE trials...
00:53 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Mouse studies identified a prodrug of a TrkB agonist that could help treat AD. Chemical synthesis and testing in mouse-based PK assays of prodrugs of a 7,8-dihydroxyflavone-based TrkB agonist yielded a carbamate-functionalized...